Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

Late last year, The Jewish Hospital-Mercy Health in Cincinnati received a first-place award in a multi-state competition for its efforts to reduce Clostridium difficile infections among inpatients.

Clostridium difficile is a common cause of infection and diarrhea in hospitalized patients, but a new study by UC Davis pathologists suggests that many patients are mistakenly diagnosed and do not ...

BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with Clostridioides difficile ...

Please provide your email address to receive an email when new articles are posted on . More patients in the bezlotoxumab group experienced recurrence vs. the placebo group (13% vs. 3%). Steroid use ...